Screening auf Chromosomenstörungen mittels Ersttrimester-Screening und non-invasive prenatal Testing

Ultraschall in der Medizin

Volumn 36, Issue 1, 2015, Pages 40-46

  Kagan, K O ^a   Hoopmann, M ^a   Hammer, R ^b   Stressig, R ^b   Kozlowski, P ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Praenatal Medicine and Genetics Praenatalde   (Germany)

Author keywords

first trimester; NIPT; nuchal translucency; trisomy

Indexed keywords

ADULT; CHROMOSOME 13; CHROMOSOME 18; CHROMOSOME ABERRATION; CHROMOSOME DISORDER; DOWN SYNDROME; ECHOGRAPHY; EMBRYOLOGY; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GERMANY; HUMAN; PREDICTIVE VALUE; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDY; SEX CHROMOSOME ABERRATION; TRISOMY;

ADULT; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; GERMANY; HUMANS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; SEX CHROMOSOME ABERRATIONS; TRISOMY; ULTRASONOGRAPHY, PRENATAL;

EID: 84923378419     PISSN: 01724614     EISSN: 14388782     Source Type: Journal    
DOI: 10.1055/s-0034-1385059     Document Type: Article

References (34)

1. Kagan K. O., Etchegaray A., Zhou Y. et al. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol: 2009; 34 14 18
2. Kagan K. O., Wright D., Baker A. et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol: 2008; 31 618 624
3. Merz E., Thode C., Eiben B. et al. Individualized correction for maternal weight in calculating the risk of chromosomal abnormalities with first-trimester screening data. Ultraschall in Med: 2011; 32 33 39
4. Kagan K. O., Eiben B., Kozlowski P. Kombiniertes Ersttrimesterscreening und zellfreie fetale DNA-«Next Generation Screening» Ultraschall in Med: 2014; 35 03 229 236
5. Benn P., Cuckle H., Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol: 2013; 42 15 33
6. Tercanli S., Vial Y., Merz E. Nicht invasiver Chromosomentest wirft neue Fragen in der Pränataldiagnostik nach der Bedeutung des Ultraschalls und Fragen nach neuen Screeningstrategien auf. Ultraschall in Med: 2013; 34 417 420
7. Eiben B., Thode C., Merz E. Nichtinvasive Pränataldiagnostik Serumtestsysteme zur Erfassung von Chromosomenanomalien. Gynäkologie+ Geburtshilfe: 2013; 18 34 37
8. Eiben B., Glaubitz R., Merz E. Trisomie-21-Analyse aus mütterlichem Blut. frauenarzt.de: 2012; 53 834 835
9. Kagan K., Hoopmann M., Kozlowski P. Assessment of Foetal DNA in Maternal Blood-A Useful Tool in the Hands of Prenatal Specialists. Geburtsh Frauenheilk: 2012; 72 998 1003
10. Nicolaides K. H., Wright D., Poon L. C. et al. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol: 2013; 42 41 50
11. Grati F. R., Barlocco A., Grimi B. et al. Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes. Am J Med Genet: 2010; 152A 1434 1442
12. Wright D., Kagan K. O., Molina F. S. et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol: 2008; 31 376 383
13. Wright D., Spencer K., Kagan K. K. et al. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation. Ultrasound Obstet Gynecol: 2010; 36 404 411
14. Cuckle H. S., Wald N. J., Thompson S. G. Estimating a womans risk of having a pregnancy associated with Downs syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol: 1987; 94 387 402
15. Snijders R. J., Sundberg K., Holzgreve W. et al. Maternal age-and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol: 1999; 13 167 170
16. Kagan K. O., Wright D., Spencer K. et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol: 2008; 31 493 502
17. Gil M. M., Akolekar R., Quezada M. S. et al. Analysis of Cell-Free DNA in Maternal Blood in Screening for Aneuploidies: Meta-Analysis. Fetal Diagn Ther: 2014
18. Nicolaides K. H., Syngelaki A., Del Mar Gil M et al. Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood. Fetal Diagn Ther: 2013; accepted.
19. Syngelaki A., Chelemen T., Dagklis T. et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn: 2011; 31 90 102
20. Leung T. Y., Vogel I., Lau T. K. et al. Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype. Ultrasound Obstet Gynecol: 2011; 38 314 319
21. Wapner R. J., Martin C. L., Levy B. et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med: 2012; 367 2175 2184
22. Rijhsinghani A., Yankowitz J., Strauss R. A. et al. Risk of preeclampsia in second-trimester triploid pregnancies. Obstet Gynecol: 1997; 90 884 888
23. Bartlett L. A., Berg C. J., Shulman H. B. et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol: 2004; 103 729 737
24. Cuckle H., Benn P., Pergament E. Maternal cfDNA screening for Down syndrome-a cost sensitivity analysis. Prenat Diagn: 2013; 33 636 642
25. GeburtenMutterBiologischesAlter.html. Available from: https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Geburten/Tabellen/GeburtenMutterBiologischesAlter.html Accessed on: 1.12.2013
26. Lathi R. B., Gray Hazard F. K., Heerema-McKenney A. et al. First trimester miscarriage evaluation. Semin Reprod Med: 2011; 29 463 469
27. Nicolaides K. H., Syngelaki A., Ashoor G. et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol: 2012; 207 374.e1 374.e6
28. Song Y., Liu C., Qi H. et al. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn: 2013; 33 700 706
29. Dan S., Wang W., Ren J. et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11105 pregnancies with mixed risk factors. Prenat Diagn: 2012; 32 1225 1232
30. Palomaki G. E., Deciu C., Kloza E. M. et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med: 2012; 14 296 305
31. Ashoor G., Syngelaki A., Wagner M. et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol: 2012; 206 322.e1 322.e5
32. Norton M. E., Brar H., Weiss J. et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol: 2012; 207 137.e1 137.e8
33. Ashoor G., Syngelaki A., Wang E. et al. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol: 2013; 41 21 25
34. Mazloom A. R., DŽakula Z., Oeth P. et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn: 2013; 33 591 597